W. Karpiesiuk
University of Kentucky
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by W. Karpiesiuk.
Journal of Veterinary Pharmacology and Therapeutics | 2009
Levent Dirikolu; W. Karpiesiuk; Andreas F. Lehner; Charlie Hughes; David E. Granstrom; Thomas Tobin
Triazine-based antiprotozoal agents are known for their lipophylic characteristics and may therefore be expected to be well absorbed following oral administration. However, although an increase in lipid solubility generally increases the absorption of chemicals, extremely lipid-soluble chemicals may dissolve poorly in gastrointestinal (GI) fluids, and their corresponding absorption and bioavailability would be low. Also, if the compound is administered in solid form and is relatively insoluble in GI fluids, it is likely to have limited contact with the GI mucosa, and therefore, its rate of absorption will be low. Based on the above considerations, we sought a solvent with low or no toxicity that would maintain triazine agents in solution. As the oral route is most preferred for daily drug therapy, such a solvent would allow an increased rate of absorption following oral administration. In present study, it was demonstrated that dimethylsulfoxide (DMSO) increased the oral bioavailability of toltrazuril sulfone (Ponazuril) threefold, relative to oral administrations of toltrazuril sulfone suspended in water. The cross-over study of toltrazuril sulfone formulated in DMSO indicated that the absolute oral bioavailability of toltrazuril sulfone in DMSO is 71%. The high bioavailability of the DMSO-preparation suggests that its daily oral administration will routinely yield effective plasma and cerebral spinal fluid (CSF) concentrations in all horses treated. Also, this improved formulation would allow clinicians to administer loading doses of toltrazuril sulfone in acute cases of Equine Protozoal Myeloencephalitis. Another option would involve administration of toltrazuril sulfone in DMSO mixed with feed (1.23 kg daily dose) meeting the US Food and Drug Administration (FDA) recommendations for the levels of DMSO permissible in pharmaceutical preparations.
Journal of Veterinary Pharmacology and Therapeutics | 2009
L. Dirikolu; Andreas F. Lehner; J. D. Harkins; W. E. Woods; W. Karpiesiuk; Richard S. Gates; M. Fisher; Thomas Tobin
Pyrilamine is an antihistamine used in human and veterinary medicine. As antihistamines produce central nervous system effects in horses, pyrilamine has the potential to affect the performance of racehorses. In the present study, O-desmethylpyrilamine (O-DMP) was observed to be the predominant equine urinary metabolite of pyrilamine. After intravenous (i.v.) administration of pyrilamine (300 mg/horse), serum pyrilamine concentrations declined from about 280 ng/mL at 5 min postdose to about 2.5 ng/mL at 8 h postdose. After oral administration of pyrilamine (300 mg/horse), serum concentrations peaked at about 33 ng/mL at 30 min, falling to <2 ng/mL at 8 h postdose. Pyrilamine was not detected in serum samples at 24 h postdosing by either route. After i.v. injection of pyrilamine (300 mg/horse) O-DMP was recovered at a level of about 20 microg/mL at 2 h postdose thereafter declining to about 2 ng/mL at 168 h postdose. After oral administration, the O-DMP recovery peaked at about 12 microg/mL at 8 h postdose and declined to <2 ng/mL at 168 h postdose. These results show that pyrilamine is poorly bioavailable orally (18%), and can be detected by sensitive enzyme-linked immunosorbent assay tests in urine for up to 1 week after a single administration. Care should be taken as the data suggest that the withdrawal time for pyrilamine after repeated oral administrations is likely to be at least 1 week or longer.
Journal of Veterinary Pharmacology and Therapeutics | 2012
Levent Dirikolu; W. Karpiesiuk; A. F. Lehner; Thomas Tobin
Toltrazuril sulfone (ponazuril) is a triazine-based antiprotozoal agent with clinical application in the treatment of equine protozoal myeloencephalomyelitis (EPM). In this study, we synthesized and determined the bioavailability of a sodium salt formulation of toltrazuril sulfone that can be used for the treatment and prophylaxis of EPM in horses. Toltrazuril sulfone sodium salt was rapidly absorbed, with a mean peak plasma concentration of 2400 ± 169 (SEM) ng/mL occurring at 8 h after oral-mucosal dosing and was about 56% bioavailable compared with the i.v. administration of toltrazuril sulfone in dimethylsulfoxide (DMSO). The relative bioavailability of toltrazuril sulfone suspended in water compared with toltrazuril sulfone sodium salt was 46%, indicating approximately 54% less oral bioavailability of this compound suspended in water. In this study, we also investigated whether this salt formulation of toltrazuril sulfone can be used as a feed additive formulation without significant reduction in oral bioavailability. Our results indicated that toltrazuril sulfone sodium salt is relatively well absorbed when administered with feed with a mean oral bioavailability of 52%. Based on these data, repeated oral administration of toltrazuril sulfone sodium salt with or without feed will yield effective plasma and cerebrospinal fluid (CSF) concentrations of toltrazuril sulfone for the treatment and prophylaxis of EPM and other protozoal diseases of horses and other species. As such, toltrazuril sulfone sodium salt has the potential to be used as feed additive formulations for both the treatment and prophylaxis of EPM and various other apicomplexan diseases.
Journal of Veterinary Pharmacology and Therapeutics | 1998
J. D. Harkins; Mundy Gd; W. E. Woods; Andreas F. Lehner; W. Karpiesiuk; Rees Wa; Levent Dirikolu; Bass S; W.G. Carter; J. Boyles; Thomas Tobin
Journal of Analytical Toxicology | 2001
Andreas F. Lehner; J. D. Harkins; W. Karpiesiuk; W. E. Woods; N. E. Robinson; Levent Dirikolu; M. Fisher; Thomas Tobin
Journal of Analytical Toxicology | 2004
Andreas F. Lehner; Charlie Hughes; J. D. Harkins; C. Nickerson; B. Mollett; Levent Dirikolu; J. Bosken; F. C. Camargo; J. Boyles; Amy Troppmann; W. Karpiesiuk; W. E. Woods; Thomas Tobin
Chromatographia | 2004
Andreas F. Lehner; Charlie Hughes; W. Karpiesiuk; F. C. Camargo; J. D. Harkins; W. E. Woods; J. Bosken; J. Boyles; Amy Troppmann; Thomas Tobin
Journal of Analytical Toxicology | 2000
Andreas F. Lehner; P. Almeida; J. Jacobs; J. D. Harkins; W. Karpiesiuk; W. E. Woods; Levent Dirikolu; J. Bosken; W.G. Carter; J. Boyles; C. Holtz; T. Heller; C. Nattrass; M. Fisher; Thomas Tobin
Veterinary Therapeutics | 2006
Levent Dirikolu; W. Karpiesiuk; Andreas F. Lehner; Charlie Hughes; W. E. Woods; J. D. Harkins; J. Boyles; Alfonza Atkinson; David E. Granstrom; Thomas Tobin
Journal of Veterinary Pharmacology and Therapeutics | 2000
Levent Dirikolu; Andreas F. Lehner; W. Karpiesiuk; J. D. Harkins; W. E. Woods; W.G. Carter; J. Boyles; M. Fisher; Thomas Tobin